首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A LUNG DISEASE COMPRISING MESENCHYMAL STEM CELLS HAVING IMPROVED PROLIFERATION AND DIFFERENTIATION CAPACITY

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A LUNG DISEASE COMPRISING MESENCHYMAL STEM CELLS HAVING IMPROVED PROLIFERATION AND DIFFERENTIATION CAPACITY

机译:预防或治疗包含间充质干细胞的肺疾病的增生和分化能力得到改善的药物组合物

摘要

Provided in the present invention are a pharmaceutical composition for preventing or treating lung diseases, comprising mesenchymal stem cells having improved proliferation and differentiation capacity, whether to express a specific cell marker, and a method for obtaining mesenchymal stem cells having improved proliferation and differentiation capacity, on the basis of the expression of the specific cell marker. According to the method of the present invention, the mesenchymal stem cells having excellent proliferation and differentiation capacity can be obtained in a convenient manner, on the basis of the expression of CD26, CD49f, CD146, and EGFR from the mesenchymal stem cells obtained from various sources. The obtained mesenchymal stem cells can be efficiently used for preventing or treating lung disease, comprising pulmonary emphysema.
机译:本发明提供了一种用于预防或治疗肺部疾病的药物组合物,其包含增殖和分化能力增强的间充质干细胞,是否表达特定的细胞标志物,以及获得增殖和分化能力增强的间充质干细胞的方法,根据特定细胞标志物的表达。根据本发明的方法,可以基于得自各种人的间充质干细胞的CD26,CD49f,CD146和EGFR的表达,以便利的方式获得具有优异的增殖和分化能力的间充质干细胞。资料来源。所获得的间充质干细胞可以有效地用于预防或治疗包括肺气肿的肺部疾病。

著录项

  • 公开/公告号KR20160108190A

    专利类型

  • 公开/公告日2016-09-19

    原文格式PDF

  • 申请/专利权人 MEDIPOST CO. LTD.;

    申请/专利号KR20160025484

  • 申请日2016-03-03

  • 分类号A61K35/28;A61K35/34;A61K35/35;A61K35/36;A61K35/48;A61K35/50;A61K35/51;C12N5/0775;

  • 国家 KR

  • 入库时间 2022-08-21 14:13:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号